BioXell confirms strong potential of Elocalcitol
- Efficacy on key parameters of BPH disease progression: arrest of prostate growth, improvement in maximum urinary flow rate (Qmax), and prevention of both Acute Urinary Retention (AUR) and the need for surgery
- Efficacy in treating lower urinary tract symptoms (LUTS): improvement on urgency, frequency and nocturia
- Safety profile comparable to or better than placebo, with lower incidence of sexual side effects; extremely well tolerated and accepted by patients
The new data for Elocalcitol are consistent with the positive effect on LUTS already observed in a Phase IIa clinical trial in Overactive Bladder (OAB). Based on on-going consultations with its advisory boards and key opinion leaders, the Company will define its Phase III development plan for Elocalcitol in BPH.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.